Results 251 to 260 of about 158,411 (308)
Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy. [PDF]
Cardiol TherPresume J, Ferreira J, Ribeiras R.
europepmc +1 more source
Oral Anticoagulation Therapy in Atrial Fibrillation Patients with Intermediate Stroke Risk: A Systematic Review and Meta-Analysis. [PDF]
Clin Appl Thromb HemostYu Z, Chen X, Zhu W.
europepmc +1 more source
Pharmacodynamic Modeling of Warfarin Dosing Algorithm for Cardiovascular Patients in Indonesia: A Tailored Method to Anticoagulation Therapy. [PDF]
Drug Des Devel TherPutriana NA +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
British Journal of Hospital Medicine, 2008
Every junior doctor will have to prescribe some form of anticoagulation therapy for their patients. Foundation year 1 doctors should be familiar with the use of warfarin and heparin as anticoagulants, and be able to prescribe them appropriately, safely and effectively. The use of these drugs is outlined here.
R, Shakur +3 more
openaire +2 more sources
Every junior doctor will have to prescribe some form of anticoagulation therapy for their patients. Foundation year 1 doctors should be familiar with the use of warfarin and heparin as anticoagulants, and be able to prescribe them appropriately, safely and effectively. The use of these drugs is outlined here.
R, Shakur +3 more
openaire +2 more sources
Anticoagulation clinics and the monitoring of anticoagulant therapy
International Journal of Cardiology, 1988Patients attending an anticoagulation clinic were studied to delineate predisposing risk factors for bleeding and thromboembolic episodes. Seventy-three patients were observed for a total of 921.8 patient-treatment months. The mean duration of treatment was 12.6 months (range 3-36 months).
R, Charney +3 more
openaire +2 more sources
Pharmacologic Therapies in Anticoagulation
Medical Clinics of North America, 2016Anticoagulants are beneficial for prevention and treatment of venous thromboembolism and stroke prevention in atrial fibrillation. The development of target-specific oral anticoagulants is changing the landscape of anticoagulation therapy and created growing interest on this subject.
Joana Lima, Ferreira, Joyce E, Wipf
openaire +2 more sources
Annual Review of Medicine, 2005
The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined ...
Lori-Ann, Linkins, Jeffrey I, Weitz
openaire +2 more sources
The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined ...
Lori-Ann, Linkins, Jeffrey I, Weitz
openaire +2 more sources
Anticoagulant therapy with ancrod
Critical Reviews in Oncology/Hematology, 19935.7. 5.8 ......... . . Treatment of venous thromboembolism 5.1.1. Deep venous thrombosis 5.1.2. Pulmonaryembolus Prophylaxis of venous thromboembolism Other venous thrombotic disorders Treatment of arterial thromboembolism 5.4.
R L, Soutar, J S, Ginsberg
openaire +2 more sources
Anticoagulation Therapy in Children
Seminars in Thrombosis and Hemostasis, 2003Thromboembolic events (TEs) in children are rare but are becoming a recognized cause of morbidity and mortality, particularly in children with serious underlying primary conditions such as congenital heart disease, cancer, or prematurity. Neonates, infants, and adolescents are most at risk for developing TEs among children, and the presence of a ...
Shoshana, Revel-Vilk, Anthony K C, Chan
openaire +4 more sources